These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

354 related items for PubMed ID: 15520088

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants.
    Singleton R, Dooley L, Bruden D, Raelson S, Butler JC.
    Pediatr Infect Dis J; 2003 Jun; 22(6):540-5. PubMed ID: 12799511
    [Abstract] [Full Text] [Related]

  • 8. Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit?
    Geskey JM, Ceneviva GD, Brummel GL, Graff GR, Javier MC.
    Clin Ther; 2004 Dec; 26(12):2130-7. PubMed ID: 15823776
    [Abstract] [Full Text] [Related]

  • 9. The use of palivizumab monoclonal antibody to control an outbreak of respiratory syncytial virus infection in a special care baby unit.
    Cox RA, Rao P, Brandon-Cox C.
    J Hosp Infect; 2001 Jul; 48(3):186-92. PubMed ID: 11439005
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Experience with the use of palivizumab together with infection control measures to prevent respiratory syncytial virus outbreaks in neonatal intensive care units.
    Kurz H, Herbich K, Janata O, Sterniste W, Bauer K.
    J Hosp Infect; 2008 Nov; 70(3):246-52. PubMed ID: 18799241
    [Abstract] [Full Text] [Related]

  • 14. Severe respiratory syncytial virus bronchiolitis: epidemiologic variations associated with the initiation of palivizumab in severely premature infants with bronchopulmonary dysplasia.
    Grimaldi M, Gouyon B, Michaut F, Huet F, Gouyon JB, Burgundy Perinatal Network.
    Pediatr Infect Dis J; 2004 Dec; 23(12):1081-5. PubMed ID: 15626942
    [Abstract] [Full Text] [Related]

  • 15. Respiratory syncytial virus (RSV) loads in premature infants with and without prophylactic RSV fusion protein monoclonal antibody.
    DeVincenzo JP, Aitken J, Harrison L.
    J Pediatr; 2003 Jul; 143(1):123-6. PubMed ID: 12915838
    [Abstract] [Full Text] [Related]

  • 16. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
    Wegner S, Vann JJ, Liu G, Byrns P, Cypra C, Campbell W, Stiles A.
    Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623
    [Abstract] [Full Text] [Related]

  • 17. [Palivizumab immunoprophylaxis: use in clinical practice, safety and beneficial effects in France].
    Pinquier D, Gouyon JB, Fauroux B, Mons F, Vicaut E, Bendjenana H, Rouffiac E, Marret S, Aujard Y.
    Arch Pediatr; 2009 Nov; 16(11):1443-52. PubMed ID: 19767182
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.